| St. Paul Opticians, Inc. | |
| 2080 Woodwinds Drive, Suite 230, Woodbury, Minnesota 55125 | |
| (651) 578-6952 |
| Name | St. Paul Opticians, Inc. |
|---|---|
| Organization Name | St Paul Opticians Inc |
| Location | 2080 Woodwinds Drive, Suite 230, Woodbury, Minnesota 55125 |
| Type | Eyewear Supplier (Equipment, not the service) |
| Phone | (651) 578-6952 |
| Participate in Medicare | Medicare enrolled and may accept medicare assignment. Please check with the supplier if they accept medicare-approved amount before you get your prescription drugs, equipment or supplies from this supplier. |
News Archive
Endologix, Inc., developer and marketer of innovative treatments for aortic disorders, today announced financial results for the three months ended March 31, 2011.
NeuroVive Pharmaceutical and Hospices Civils de Lyon (HCL) today announced the enrollment and treatment of the first patient in the European multicenter trial of myocardial infarction (the CIRCUS study). NeuroVive's advanced CicloMulsion(TM) cremophor-free IV cyclosporine formulation is used in this study of 1,000 patients undergoing percutaneous coronary intervention (PCI) for acute myocardial infarction to examine cyclosporine's ability to protect cardiac tissue.
Polyplus-transfection SA, a privately-held company developing innovative technologies for molecular and cellular biology, announces today that it has granted two agencies of the United States National Institutes of Health a non-exclusive, research license to use Polyethylenimine (PEI) for in vitro transfection applications. The two agencies are the National Institute of Allergy and Infectious Diseases and the National Cancer Institute.
A new study published in the journal Environmental Science & Technology Letters reports that particulate matter smaller than a single micron in diameter, called PM1, is strongly linked to the occurrence of cardiovascular disease (CVD). This is thought to be due to its higher surface area to volume ratio.
› Verified 7 days ago
| NPI Number | 1124456413 |
| Organization Name | ST. PAUL OPTICIANS, INC. |
| Type | Eyewear Supplier (Equipment, not the service) |
| Address | 2080 Woodwinds Dr, Suite 230, Woodbury, MN 55125 |
| Phone Number | 651-578-6952 |
News Archive
Endologix, Inc., developer and marketer of innovative treatments for aortic disorders, today announced financial results for the three months ended March 31, 2011.
NeuroVive Pharmaceutical and Hospices Civils de Lyon (HCL) today announced the enrollment and treatment of the first patient in the European multicenter trial of myocardial infarction (the CIRCUS study). NeuroVive's advanced CicloMulsion(TM) cremophor-free IV cyclosporine formulation is used in this study of 1,000 patients undergoing percutaneous coronary intervention (PCI) for acute myocardial infarction to examine cyclosporine's ability to protect cardiac tissue.
Polyplus-transfection SA, a privately-held company developing innovative technologies for molecular and cellular biology, announces today that it has granted two agencies of the United States National Institutes of Health a non-exclusive, research license to use Polyethylenimine (PEI) for in vitro transfection applications. The two agencies are the National Institute of Allergy and Infectious Diseases and the National Cancer Institute.
A new study published in the journal Environmental Science & Technology Letters reports that particulate matter smaller than a single micron in diameter, called PM1, is strongly linked to the occurrence of cardiovascular disease (CVD). This is thought to be due to its higher surface area to volume ratio.
› Verified 7 days ago
| NPI Number | 1669574646 |
| Organization Name | ST PAUL EYE CLINIC PA |
| Type | Eyewear Supplier (Equipment, not the service) |
| Address | 2080 Woodwinds Dr, Suite 230, Woodbury, MN 55125 |
| Phone Number | 651-738-6800 |
News Archive
Endologix, Inc., developer and marketer of innovative treatments for aortic disorders, today announced financial results for the three months ended March 31, 2011.
NeuroVive Pharmaceutical and Hospices Civils de Lyon (HCL) today announced the enrollment and treatment of the first patient in the European multicenter trial of myocardial infarction (the CIRCUS study). NeuroVive's advanced CicloMulsion(TM) cremophor-free IV cyclosporine formulation is used in this study of 1,000 patients undergoing percutaneous coronary intervention (PCI) for acute myocardial infarction to examine cyclosporine's ability to protect cardiac tissue.
Polyplus-transfection SA, a privately-held company developing innovative technologies for molecular and cellular biology, announces today that it has granted two agencies of the United States National Institutes of Health a non-exclusive, research license to use Polyethylenimine (PEI) for in vitro transfection applications. The two agencies are the National Institute of Allergy and Infectious Diseases and the National Cancer Institute.
A new study published in the journal Environmental Science & Technology Letters reports that particulate matter smaller than a single micron in diameter, called PM1, is strongly linked to the occurrence of cardiovascular disease (CVD). This is thought to be due to its higher surface area to volume ratio.
› Verified 7 days ago
News Archive
Endologix, Inc., developer and marketer of innovative treatments for aortic disorders, today announced financial results for the three months ended March 31, 2011.
NeuroVive Pharmaceutical and Hospices Civils de Lyon (HCL) today announced the enrollment and treatment of the first patient in the European multicenter trial of myocardial infarction (the CIRCUS study). NeuroVive's advanced CicloMulsion(TM) cremophor-free IV cyclosporine formulation is used in this study of 1,000 patients undergoing percutaneous coronary intervention (PCI) for acute myocardial infarction to examine cyclosporine's ability to protect cardiac tissue.
Polyplus-transfection SA, a privately-held company developing innovative technologies for molecular and cellular biology, announces today that it has granted two agencies of the United States National Institutes of Health a non-exclusive, research license to use Polyethylenimine (PEI) for in vitro transfection applications. The two agencies are the National Institute of Allergy and Infectious Diseases and the National Cancer Institute.
A new study published in the journal Environmental Science & Technology Letters reports that particulate matter smaller than a single micron in diameter, called PM1, is strongly linked to the occurrence of cardiovascular disease (CVD). This is thought to be due to its higher surface area to volume ratio.
› Verified 7 days ago
Allina Health Woodbury Clinic Type: Clinic Pharmacy Location: 8675 Valley Creek Rd, Woodbury, Minnesota 55125 Phone: (651) 241-3000 | |
Associted Eye Care Optical Llc Type: Medicare Supplier Location: 237 Radio Dr, Woodbury, Minnesota 55125 Phone: (651) 275-3000 | |
Corner Home Medical Type: DME Supplier - Oxygen Equipment & Supplies Location: 8380 City Centre Dr, Woodbury, Minnesota 55125 Phone: (952) 388-0500 | |
Fairview Home Medical Equipment- Wo Type: Durable Medical Equipment & Medical Supplies Supplier Location: 1925 Woodwinds Dr, Woodbury, Minnesota 55125 Phone: (651) 683-7010 | |
Fairview Orthotics And Prosthetics- Type: DME Supplier - Customized Equipment Location: 1875 Woodwinds Dr, Woodbury, Minnesota 55125 Phone: (651) 683-7000 |